BCIQ Profiles

Company Profile Report
0604 Stablix ECP
BioCentury & Getty Images

Emerging Company Profile

Stablix takes targeted protein degradation’s tactics in reverse

Emerging Company Profile: Versant’s protein stabilization play has $63M to develop ‘RESTORACS’ for rare diseases, cancer and autoimmunity

Versant-founded targeted protein stabilization company Stablix is using its $63 million series A round to develop ‘RESTORACS’ for rare diseases, cancer and autoimmunity.

Jun 4, 2021 | 9:26 PM GMT

Stablix is the among the first companies founded to extend the logic of protein degradation to a different enzymatic process — in this case, stabilizing proteins via deubiquitination.

The company emerged from stealth Thursday with a $63 million

Read the full 984 word article

How to gain access

Continue reading with a
two-week free trial.